Effectiveness of GLP-1 Receptor Agonists in T2DM and Obesity
BMJ Open
Summary
This retrospective cohort study evaluates the impact of GLP-1 receptor agonists on BMI and blood glucose levels in patients with T2DM and obesity. Using difference-in-difference analysis, it compares GLP-1RA with other second-line antidiabetic treatments over a 24-month period. Findings indicate significant BMI reduction and improved glycaemic control in the GLP-1RA group, suggesting its preference for obese T2DM patients not responsive to metformin monotherapy.
Study Design
Interventions
Study Type
Outcomes
Duration and Size
Study Population
Geography
Methodology
Data were collected retrospectively from patients receiving GLP-1RA or other second-line treatments. Analysis used linear mixed-effect regression with inverse probability weighting to adjust for confounders.
Interventions
Interventions included GLP-1RAs such as exenatide, liraglutide, and semaglutide administered over 24 months.
Key Findings
GLP-1RA treatments led to greater reductions in BMI and blood glucose compared with other therapies, supporting their use for T2DM with obesity.
Comparison with other Studies
The findings align with previous RCTs and observational studies indicating sustained BMI and glucose improvements with GLP-1RA.
Journal Reference
Siriyotha S, Anothaisintawee T, Looareesuwan P, et al. Effectiveness of GLP-1 receptor agonists for reduction of BMI and blood glucose in T2DM. BMJ Open. 2024;14:e086424. doi:10.1136/bmjopen-2024-086424.
Related and Discussions
Key References
Most relevant evidence and guidance related to this research.
Supporting Evidence
Supporting evidence and related resources.
The Future of GLP-1 Receptor Agonists: A Precision Medicine Approach
Expert Discusses GLP-1 Receptor Agonists for Treatment of Diabetes
GLP-1 Receptor Agonists: An Overview
GLP-1 Agonists for Type 2 Diabetes
GLP-1 Receptor Agonists in Type 2 Diabetes Treatment
GLP-1 Receptor Agonists: Benefits and Side Effects
30 total sources in this category